B:SM will break its investment record this year with 62 million euros
War in Ukraine: when kyiv attacks Russia with inflatable balloons loaded with explosives
United States: divided on the question of presidential immunity, the Supreme Court offers respite to Trump
Maurizio Molinari: “the Scurati affair, a European injury”
Inflation rises to 3.3% in April and core inflation moderates to 2.9%
Pedro Sánchez announces that he continues "with more strength" as president of the Government
Irritable bowel syndrome: the effectiveness of low-carbohydrate diets is confirmed
Beware of the three main sources of poisoning in children
Relief at Bercy: Moody’s does not sanction France
More than 10 million holders, 100 billion euros: the Retirement Savings Plan is a hit
Paris 2024 Olympic Games: the extension of line 14 will open “at the end of June”, confirms Valérie Pécresse
Failing ventilators: Philips to pay $1.1 billion after complaints in the United States
The Cannes Film Festival welcomes Omar Sy, Eva Green and Kore-Eda to its jury
Prisoner in Israel, a Palestinian receives the International Prize for Arab Fiction
Harvey Weinstein, the former American producer hospitalized in New York
New success for Zendaya, tops the North American box office with Challengers
Skoda Kodiaq 2024: a 'beast' plug-in hybrid SUV
Tesla launches a new Model Y with 600 km of autonomy at a "more accessible price"
The 10 best-selling cars in March 2024 in Spain: sales fall due to Easter
A private jet company buys more than 100 flying cars
This is how housing prices have changed in Spain in the last decade
The home mortgage firm drops 10% in January and interest soars to 3.46%
The jewel of the Rocío de Nagüeles urbanization: a dream villa in Marbella
Rental prices grow by 7.3% in February: where does it go up and where does it go down?
Europeans: a senior official on the National Rally list
Blockade of Sciences Po: the right denounces a “drift”, the government charges the rebels
Even on a mission for NATO, the Charles-de-Gaulle remains under French control, Lecornu responds to Mélenchon
“Deadly Europe”, “economic decline”, immigration… What to remember from Emmanuel Macron’s speech at the Sorbonne
These French cities that will boycott the World Cup in Qatar
NBA: young Thunder coach Mark Daigneault named coach of the year
Athletics: Noah Lyles in legs in Bermuda
Serie A: Dumfries celebrates Inter Milan title with humiliating sign towards Hernandez
Tennis: no pity for Sorribes, Swiatek is in the quarterfinals in Madrid
The Mainz-based pharmaceutical company Biontech has taken an important step towards bringing its mRNA-based cancer vaccines onto the market. The clinical trials on thousands of patients agreed in Great Britain are to begin this year, the “Spiegel” reported on Sunday.
The vaccine candidates, types of cancer and locations are currently being selected for this. With its British partners, Biontech wants to ensure that the procedure soon becomes part of everyday treatment. "We believe that this will be possible on a larger scale for patients before 2030," said CEO Ugur Sahin the news magazine.
The technology is far advanced. "In 2014, it took us three to six months to produce an individualized cancer vaccine; we're currently at four to six weeks," explained the company's founder. "Our goal is to come in well under four weeks."
There is also promising evidence of effectiveness, said Sahin's wife Özlem Türeci, co-founder and medical director of Biontech. The company is currently researching several mRNA cancer vaccines. "For some of these candidates we see evidence of clinical activity." This means that the immune system is activated, "so that in some patients the cancer becomes visibly smaller or disappears and relapses occur less frequently".
"Aha! Ten minutes of everyday knowledge” is WELT’s science podcast. Subscribe to the podcast on Spotify, Apple Podcasts, Deezer, Amazon Music, among others, or directly via RSS feed.
